Kevan C. Herold, MD, C.N.H. Long Professor of Immunology and professor of medicine (endocrinology) at Yale School of Medicine, was recently appointed TrialNet Chair, succeeding Carla J. Greenbaum, MD, who served six years in the position.

Dr. Herold’s research focuses on translational immunology, through which he seeks to understand the basis for autoimmune diseases such as T1D and their mechanisms, and uses that knowledge to develop new therapies. That work includes understanding how beta cells, which produce, store, and release insulin, are destroyed and react to inflammation.

“We are in a new era in the treatment and prevention of Type 1 diabetes,” says Herold. “For the first time, we have been able to effectively delay the disease in those at risk. I am very honored to be leading this group that we hope will find ways to make Type 1 diabetes, one of the most frequent childhood illnesses, a disease of the past.”

Dr. Herold became chair on June 1. He is just the third person to hold the position since TrialNet was founded as the Type 1 Diabetes Prevention Trial (DPT-1) in 1993. He follows Jay Skyler, MD, of the University of Miami Miller School of Medicine, who served from 1993 to 2015, and Carla Greenbaum, MD, of the Benaroya Research Institute in Seattle, who succeeded Skyler in 2015.

Dr. Carla Greenbaum will remain a part of TrialNet leadership as the Director of the TrialNet Hub, as well as the Clinical Center Director for the Benaroya Research Institute in Seattle, WA.

We thank Dr. Greenbaum for her dedication to TrialNet as the TrialNet chair and welcome Dr. Herold into his new role.